Increased levels of soluble fas receptor and fas ligand in the cerebrospinal fluid of HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 16, Issue 3, 2000, Pages 221-226

  Sporer, Bernd ^a   Koedel, Uwe ^a   Goebel, Frank Detlef ^b   Pfister, Hans Walter ^a,b  

^a Department of Neurology ^*  (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FAS ANTIGEN; LIGAND;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD95; CD4 LYMPHOCYTE COUNT; FAS LIGAND PROTEIN; HIV INFECTIONS; HUMANS; MEMBRANE GLYCOPROTEINS; SOLUBILITY;

EID: 0034628621     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200309313     Document Type: Article

References (26)

1. 1. Becher B, Barker PA, Owens T, and Antel JP: CD95-CD95L. Can the brain learn from the immune system? Trends Neurosci 1998;21: 114-117.
2. 2. Kayagaki N, Kawasaki A, Ebata T, et al.: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-1783.
3. 3. Rensing EA, Hess S, Ziegler HH, Riethmuller G, and Engelmann H: Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J Inflamm 1995;45:161-174.
4. 4. Sekine C, Yagita H, Kobata T, Hasunuma T, Nishioka K, and Okumura K: Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis. Biochem Biophys Res Commun 1996;228:14-20.
5. 5. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, and Suda T: Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nature Med 1998;4:1287-1292.
6. 6. Mogi M, Harada M, Kondo T, et al.: The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 1996; 220:195-198.
7. 7. Dowling P, Shang G, Raval S, Menonna J, Cook S, and Husar W: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996;184:1513-1518.
8. 8. Nishimura T, Akiyama H, Yonehara S, et al.: Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res 1995;695:137-145.
9. 9. Inoue A, Koh C-S, Sakai T, et al.: Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J Neuroimmunol 1997;75:141-146.
10. 10. Ertel W, Keel M, Stocker R, et al.: Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury. J Neuroimmunol 1997;80:93-96.
11. 11. Aries SP, Schaaf B, Muller C, Dennin RH, and Dalhoff K: Fas (CD95) expression on CD4+ T cells from HIV-infected patients increases with disease progression. J Mol Med 1995;73:591-593.
12. 12. Fadeel B, Samuelsson A, Hachiya T, Brostrom C, and Chiodi F: Elevated serum levels of soluble Fas/APO-1 in human immunodeficiency virus-infected individuals. Blood 1996;88:4727-4730. [Letter]
13. 13. Jiang JD, Schlesinger M, Sacks H, Mildvan D, Roboz JP, and Bekesi JG: Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+ , CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status. J Clin Immunol 1997;17:185-192.
14. 14. Katsikis PD, Wunderlich ES, Smith CA, and Herzenberg LA: Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995;181:2029-2036.
15. 15. Samuelsson A, Sonnerborg A, Heuts N, Coster J, and Chiodi F: Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1997;13:1031-1038.
16. 16. Sloand EM, Young NS, Kumar P, Weichold FF, Sato T, and Maciejewski JP: Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: Effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. Blood 1997;89:1357-1363.
17. 17. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, and Paya CV: Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996;70:199-206.
18. 18. Hosaka N, Oyaizu N, Kaplan MH, Yagita H, and Pahwa S: Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cell and in plasma from human immunodeficiency virus-infected patients. J Infect Dis 1998;178:1030-1039.
19. 19. Becher B, D'Souza SD, Troutt AB, and Antel JP: Fas expression on human fetal astrocytes without susceptibility to Fas-mediated cytotoxicity. Neuroscience 1998;84:627-634.
20. 20. Choi C, Park J, Lee J, et al.: Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ. J Immunol 1999;162:1889-1895.
21. 21. Spanaus KS, Schlapbach R, and Fontana A: TNF-alpha and IFN-gamma render microglia sensitive to Fas ligand-induced apoptosis by induction of Fas expression and down-regulation of Bcl-2 and Bcl-xL. Fur J Immunol 1998;28:4398-4408.
22. 22. O'Neill A J and Kaltschmidt C: NK-κB: A crucial transcription factor for glial and neuronal function. Trends Neurosci 1997;20:252-258.
23. 23. Saas P, Boucraut J, Quiquerez AL, et al.: CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: A key role in brain inflammation? J Immunol 1999;162:2326-2333.
24. 24. Seino K, Iwabuchi K, Kayagaki N, et al.: Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998;161:4484-4488.
25. 25. Kang SM, Schneider DB, Lin Z, et al.: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 1997;3:738-743.
26. 26. Glass JD, Fedor H, Wesselingh SL, and McArthur JC: Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlation with dementia. Ann Neurol 1995;38:755.